Vaxart names W. Mark Watson as lead independent director

Vaxart Inc. (OTCQX: VXRT) appointed W. Mark Watson as lead independent director, the clinical-stage biotechnology company announced.

Watson, a certified public accountant with over 50 years of experience including more than 40 years at Deloitte Touche Tohmatsu, has served on Vaxart's board since August 2022. He has held board positions at multiple biotech companies and served as chairman of the board and audit committee at Inhibitor Therapeutics Inc., and as director and audit committee chair at Sykes Enterprises Inc. and BioDelivery Sciences International Inc.

The company said its board is developing a stock ownership policy for directors to align their interests with stockholders. The policy will formalize current stock ownership practices among board members.

Vaxart is encouraging stockholders of record as of July 29, 2025, to vote in favor of a reverse stock split proposal by 11:59 p.m. Eastern Time on September 18, 2025. The company noted that stockholders who previously voted against the proposal can change their vote.

The company will hold a special meeting of stockholders on September 19, 2025, at 8:30 a.m. Pacific Time in virtual format to address the reverse stock split proposal.

"On behalf of the Board, we believe strongly in the direction Vaxart is heading and its potential to transform global public health," Watson said. "Based on my years of investing in biotech companies and my experience serving on the boards of other publicly traded companies, regaining Nasdaq compliance is a critical step for our Company."

Vaxart develops oral recombinant vaccines using its proprietary delivery platform, with development programs including vaccines for coronavirus, norovirus, influenza, and human papillomavirus.

You May Also Be Interested In

• SpaceX files for 555.56M share IPO at $135/sh
• Aeva Technologies files mixed shelf offering registration
• Darling Ingredients receives US patent for blood glucose collagen peptide